ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?
Topic Areas:
Multiple Myeloma
Published on December 20, 2017
Where do things stand now with personalizing myeloma therapy to a patient’s genetic profile? At the American Society of Hematology (ASH) 2017 conference in Atlanta, Esther Schorr speaks with Dr. Gareth Morgan, Director of the UAMS Myeloma Institute, about new oncogenes in myeloma. They also discuss the importance of testing at the time of myeloma diagnosis to set a treatment plan. Watch for this top myeloma expert’s take on the latest myeloma research.
Produced by Patient Power. We thank AbbVie, Inc., Celgene and Takeda Oncology for their support.
